Your browser doesn't support javascript.
loading
Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency.
Delavari, Samaneh; Abolhassani, Hassan; Abolnezhadian, Farhad; Babaha, Fateme; Iranparast, Sara; Ahanchian, Hamid; Moazzen, Nasrin; Nabavi, Mohammad; Arshi, Saba; Fallahpour, Morteza; Bemanian, Mohammad Hassan; Shokri, Sima; Momen, Tooba; Sadeghi-Shabestari, Mahnaz; Molatefi, Rasol; Shirkani, Afshin; Vosughimotlagh, Ahmad; Safarirad, Molood; Sharifzadeh, Meisam; Pashangzadeh, Salar; Salami, Fereshte; Shirmast, Paniz; Rezaei, Arezou; Moeini Shad, Tannaz; Mohraz, Minoo; Rezaei, Nima; Hammarström, Lennart; Yazdani, Reza; Aghamohamamdi, Asghar.
Afiliación
  • Delavari S; Research Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Abolhassani H; Research Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. hassan.abolhassani@ki.se.
  • Abolnezhadian F; Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institute at Karolinska University Hospital Huddinge, Stockholm, Sweden. hassan.abolhassani@ki.se.
  • Babaha F; Department of Pediatrics, Abuzar Children's Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Iranparast S; Research Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Ahanchian H; Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
  • Moazzen N; Department of immunology, Faculty of Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Nabavi M; Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Arshi S; Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Fallahpour M; Department of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • Bemanian MH; Department of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • Shokri S; Department of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • Momen T; Department of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • Sadeghi-Shabestari M; Department of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • Molatefi R; Department of Allergy and Clinical Immunology, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Noncommunicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Shirkani A; Immunology research center of Tabriz, TB and lung research center of Tabriz, children hospital, Tabriz University of Medical Science, Tabriz, Iran.
  • Vosughimotlagh A; Department of Pediatrics, Bo-Ali Children's Hospital of Ardabil University of Medical Sciences, Ardabil, Iran.
  • Safarirad M; Allergy and Clinical Immunology Department, Bushehr University of Medical Sciences, School of Medicine, Bushehr, Iran.
  • Sharifzadeh M; Department of Pediatrics, North Khorasan University of Medical Sciences, Bojnurd, Iran.
  • Pashangzadeh S; Department of Pediatrics, North Khorasan University of Medical Sciences, Bojnurd, Iran.
  • Salami F; Division of Pediatric Critical Care, Children Medical Center, Tehran University of Medical Science, Tehran, Iran.
  • Shirmast P; Research Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Rezaei A; Research Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Moeini Shad T; Research Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Mohraz M; Research Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Rezaei N; Research Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Hammarström L; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
  • Yazdani R; Research Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Aghamohamamdi A; Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institute at Karolinska University Hospital Huddinge, Stockholm, Sweden.
J Clin Immunol ; 41(2): 345-355, 2021 02.
Article en En | MEDLINE | ID: mdl-33263173
ABSTRACT
Although it is estimated that COVID-19 life-threatening conditions may be diagnosed in less than 11000 infected individuals below the age of 50, but the real impact of this pandemic on pediatric patients with different types of primary immunodeficiency (PID) is not elucidated. The current prospective study on a national registry of PID patients showed that with only 1.23 folds higher incidence of infections, these patients present a 10-folds higher mortality rate compared to population mainly in patients with combined immunodeficiency and immune dysregulation. Therefore, further management modalities against COVID-19 should be considered to improve the survival rate in these two PID entities using hematopoietic stem cell transplantation and immunomodulatory agents.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 / 4_TD / 6_ODS3_enfermedades_notrasmisibles / 7_ODS3_muertes_prevenibles_nacidos_ninos Problema de salud: 2_muertes_prevenibles / 4_covid_19 / 4_pneumonia / 6_other_respiratory_diseases / 7_non_communicable_diseases Asunto principal: Evaluación del Impacto en la Salud / Enfermedades de Inmunodeficiencia Primaria / SARS-CoV-2 / COVID-19 Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: J Clin Immunol Año: 2021 Tipo del documento: Article País de afiliación: Irán
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 / 4_TD / 6_ODS3_enfermedades_notrasmisibles / 7_ODS3_muertes_prevenibles_nacidos_ninos Problema de salud: 2_muertes_prevenibles / 4_covid_19 / 4_pneumonia / 6_other_respiratory_diseases / 7_non_communicable_diseases Asunto principal: Evaluación del Impacto en la Salud / Enfermedades de Inmunodeficiencia Primaria / SARS-CoV-2 / COVID-19 Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: J Clin Immunol Año: 2021 Tipo del documento: Article País de afiliación: Irán